Author:
Thomas Rhys H,Cunningham Mark O
Abstract
Click here to listen to the PodcastThe one-third of people who do not gain seizure control through current treatment options need a revolution in epilepsy therapeutics. The general population appears to be showing a fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs. It is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread legalisation of recreational cannabis. It is important that neurologists understand the difference between artisanal cannabidiol products available legally on the high street and the cannabidiol medications that have strong trial evidence. In the UK in 2018 there are multiple high-profile reports of the response of children taking cannabis-derived medication, meaning that neurologists are commonly asked questions about these treatments in clinic. We address what an adult neurologist needs to know now, ahead of the likely licensing of Epidiolex in the UK in 2019.
Subject
Neurology (clinical),General Medicine
Reference29 articles.
1. Peripheral and Central Nervous System Drugs Advisory Committee Meeting , 2018. FDA briefing document. https://fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm604736.pdf (accessed 21 Jul 2018).
2. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms;Allan;Can Fam Physician,2018
3. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
4. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
5. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献